Caplin Point Gets USFDA Nod

  Published 8 months ago

Caplin Point received USFDA approval for generic Milrinone injection, targeting acute decompensated heart failure treatment.

  • Approval covers two Milrinone infusion dosage forms, ensuring availability in safe, effective single-dose infusion bag packaging.
  • Milrinone Lactate Injection recorded $11 million in US sales for the 12 months ending July 2025.
  • Caplin Point expands presence in regulated US markets via subsidiaries Caplin Steriles and Caplin Steriles USA Inc.

You might like these

Dynabook & Syrma SGS: India Manufacturing Boost

Mubadala Launches $ Sukuk Offering

Cipla Expands Global Reach from Chinese Factory

Adani-BYD in Talks for Battery Venture

L&T Launches Texas Tech Hub for Defense & AI Innovation

Kellton Tech Announces Stock Split & Fundraising Plans

Auto Sales Impacted by Supply Chain Issues

News that matters the most ⚡